Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer

[1] Torre LA(2015)Global cancer statistics, 2012 CA Cancer J Clin 65 87-108

[2] Bray F(2010)Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60 244-272

[3] Siegel RL(2011)Current therapeutic strategies for invasive and metastatic bladder cancer Onco Targets Ther 4 97-113

[4] Ferlay J(2016)Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology guideline): American Society of Clinical Oncology clinical practice guideline endorsement J Clin Oncol 34 1945-1952

[5] Lortet-Tieulent J(2016)New strategies in bladder cancer: a second coming for immunotherapy Clin Cancer Res 22 793-801

[6] Jemal A(2017)Checkpoint inhibitors in the treatment of urological malignancies ESMO Open 2 e000165-3125

[7] Jacobs BL(2016)Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer J Clin Oncol 34 3119-1598

[8] Lee CT(2016)Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase ½ trial Lancet Oncol 17 1590-1827

[9] Montie JE(2009)18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization J Nucl Med 50 1820-641

[10] Vishnu P(2017)Tumour functional sphericity from PET images: prognostic value in NSCLC and impact of delineation method Eur J Nucl Med Mol Imaging 45 630-391

[1] Torre LA(2015)Global cancer statistics, 2012 CA Cancer J Clin 65 87-108

[2] Bray F(2010)Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60 244-272

[3] Siegel RL(2011)Current therapeutic strategies for invasive and metastatic bladder cancer Onco Targets Ther 4 97-113

[4] Ferlay J(2016)Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology guideline): American Society of Clinical Oncology clinical practice guideline endorsement J Clin Oncol 34 1945-1952

[5] Lortet-Tieulent J(2016)New strategies in bladder cancer: a second coming for immunotherapy Clin Cancer Res 22 793-801

[6] Jemal A(2017)Checkpoint inhibitors in the treatment of urological malignancies ESMO Open 2 e000165-3125

[7] Jacobs BL(2016)Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer J Clin Oncol 34 3119-1598

[8] Lee CT(2016)Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase ½ trial Lancet Oncol 17 1590-1827

[9] Montie JE(2009)18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization J Nucl Med 50 1820-641

[10] Vishnu P(2017)Tumour functional sphericity from PET images: prognostic value in NSCLC and impact of delineation method Eur J Nucl Med Mol Imaging 45 630-391